Xcelience adds capacity for clinical trial supplies for DPIs

Contract drug developer Xcelience has added micro-dosing capacity for the manufacturing of clinical supplies for dry powder inhaler delivery systems. The addition of an MG Futura capsule filler, says the company, “improves upon production times, increases overall capacity, and expands upon our existing capabilities for powders, pellets and powder micro-dosing for inhalation systems.”

Xcellience already offers filling services using Xcelodose micro-dosing machines, and according to its web site is “the market
leader for Powder-in-Capsule Services with greater global capacity than any other service provider.” The new MG micro-dosing system is part of an expansion of the company’s manufacturing facility that also includes a new packaging line.

Read the Xcellience press release.

Share

published on

Featured event:

October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden

October 21-October 22: MVIC Symposium, Lund, Sweden

October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany

November 10-November 11: Rescon Europe 2026, Porto, Portugal